Navigation Links
EntreMed Reports Third Quarter 2007 Financial Results
Date:11/6/2007

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three and nine-month periods ending September 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2007 were approximately $3,520,000 versus $3,023,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.0 million), or ($0.04) per share. This compares with a net loss of approximately ($3.5 million), or ($0.05) per share for the same period last year.

Revenues for the nine months ending September 30, 2007 were approximately $3,520,000 versus $3,023,000 for 2006. Reported net loss for the first nine months of 2007 was ($18.6 million), or ($0.23) per share as compared to ($44.3 million) or ($0.63) per share for 2006. The 2006 nine-month net loss includes a non-cash charge of $29.5 million resulting from the acquisition of Miikana Therapeutics in January 2006. Excluding the non-cash charge, the Company's net loss for the first nine months of 2006 was ($14.8 million). As of September 30, 2007, EntreMed had cash and short-term investments of approximately $50.6 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "Royalty revenues recorded in the third quarter 2007 represent an increase over the same period last year as we continue to benefit from the increase in sales of Celgene's Thalomid(R). As a result of additional programs heading towards clinical development in 2008, we expect research and development expenses to trend up in the fourth quarter and into 2008. With the completion of the recent secured financing, we are reporting over $50 million in cash and short-term investments, an amount that will fund planned operations into 2009."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "Our progress for the first nine months of 2007 is consistent with both our guidance and my expectations. We continue to make progress with both our clinical and preclinical programs and are on track to achieve the remainder of our 2007 milestones. We are also continuing to build our oncology drug development expertise through selective additions to the management team. Last month we announced the addition of Dr. Kenneth W. Bair as Senior Vice President, Research and Development. Building a focused pipeline of multi-mechanism drug candidates with an experienced team to manage their development remain primary goals for the Company."

As previously announced, Mr. Burns will give a corporate overview today during the Rodman & Renshaw 9th Annual Healthcare Conference. Mr. Burns' presentation is scheduled for 10:15 a.m. (ET) this morning and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days. EntreMed anticipates conducting a Company update call, including preliminary guidance for 2008, in December. Dial-in information for the call will be disseminated in a separate announcement.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

EntreMed, Inc.

Associate Director

Corporate Communications &

Investor Relations

240-864-2643

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

September 30,

2007 2006

Total revenues $3,520,259 $3,023,185

Research and development 5,109,257 5,544,134

General and administrative 1,706,451 1,497,612

Acquired in-process research and

development 0 0

Net Loss (3,035,346) (3,524,998)

Net Loss per share (basic and diluted)

attributable to common shareholders $(0.04) $(0.05)

Weighted average number of shares

outstanding (basic and diluted) 84,223,912 73,288,499

Nine Months Ended

September 30,

2007 2006

Total revenues $3,520,259 $3,023,185

Research and development 18,089,240 13,813,440

General and administrative 5,407,588 5,256,958

Acquired in-process research and

development 0 29,481,894

Net Loss (18,643,625) (44,261,425)

Net Loss per share (basic)

attributable to common shareholders $(0.23) $(0.63)

Weighted average number of shares

outstanding (basic) 84,015,999 70,952,694

Cash and short-term investments $50,644,261 $39,428,618


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
6. Haemacure Reports Third Quarter 2007 Results
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , ... February 26, 2017 , ... IndustryArchive.Org . ... with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales ... the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... FCPX users ... Color tools from Pixel Film Studios. With ProSharpen Color users have total control over ... easily refine their color range. With color spectrum tools users can visually see the ...
(Date:2/24/2017)... Pittsburgh, PA (PRWEB) , ... February 24, 2017 , ... ... by researchers at the University of Pittsburgh points to eight genes that may explain ... the other, according to the results of a study published today in the journal ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Healthcare Associates ... Medical Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, ... with easy access to Highway 121. , As the practice has grown, the need ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 ITL Limited, ( ASX: ITD ), an ... the half year ended 31 December 2016 compared with the previous ... can be viewed here . Highlights ... up 104%) Earnings per share of 2.2 cents ... $17.5m (Dec 2015: $15.7m; up 11%) Profit before ...
(Date:2/23/2017)... 23. Februar 2017 Im Rahmen seiner ... Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem ... Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
Breaking Medicine Technology: